NR improved the six-minute walking distance and
treadmill walking time for those with PAD
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) research, shares results
from a milestone phase II clinical study showcasing the promising
effects of nicotinamide riboside (NR) supplementation for people
with peripheral artery disease (PAD). This study was part of the
ChromaDex External Research Program (CERP®), which donated
ChromaDex’s patented NR ingredient, Niagen®, the most efficient and
high-quality NAD+ precursor, for the advancement of this
research.
As reported in the peer-reviewed journal Nature Communications
by a team of scientists led by Dr. Mary M. McDermott, Northwestern
University Feinberg School of Medicine, Chicago, results
underscored the functional mobility benefits of NR such as an
improvement in treadmill walking time and a statistically
significant and clinically meaningful improvement in the six-minute
walking distance in individuals with PAD.
Dr. McDermott commented, “In this Phase II clinical trial, NR
improved 6-minute walk distance and treadmill walking time in
people with PAD, compared to placebo. These promising results
require confirmation in a larger definitive randomized clinical
trial.”
About PAD and the NAD+ connection
A prevalent condition impacting over 200 million people
worldwide, PAD is characterized by a narrowing or blockage of
arteries that reduces blood flow to the limbs, causing severe pain
and walking disabilities due to insufficient blood flow and reduced
oxygen supply. Existing treatments for PAD are often limited in
their effectiveness, underscoring the need for novel therapeutic
approaches.
As the most efficient NAD+ precursor, NR has been proven safe
and effective in elevating NAD+ levels in humans (Conze et al.,
2019, Martens et al., 2018, Trammell et al., 2016). Preclinical and
clinical studies have shown that boosting NAD+ levels with NR can
enhance skeletal muscle health, mitochondrial performance, and
vascular health (Lapatto et al., 2023, Elhassan et al., 2019, Zhang
et al., 2016). As NAD+ levels decline with age and given the high
incidence of PAD among older individuals, increasing NAD+ with NR
may reduce oxidative stress and improve mitochondrial and
endothelial cell function in those with PAD (Elhassan et al., 2019,
Zhang et al., 2016, Chen et al., 2010).
Dr. Andrew Shao, Vice President of Scientific Affairs at
ChromaDex, highlighted the broader implications of these findings.
“Elevating NAD+ levels using NR could have profound effects on
muscle mitochondrial function. This study reinforces the potential
of NR to support vascular health and improve functional mobility in
patients with PAD.”
Study overview
This six-month phase II randomized, double-blind clinical study
analyzed the effects of elevating NAD+ with NR supplementation
alone and in combination with resveratrol on the six-minute walking
distance in individuals with PAD.
This was a randomized, double-blind, placebo-controlled, phase
II, parallel assignment study on 90 PAD patients over a six-month
period. Participants were 50 years of age or older and randomly
assigned to one of three groups: NR (1000 mg), NR (1000 mg)
combined with resveratrol (125 mg), or placebo.
Highlights
- At the six-month follow-up, NR significantly improved treadmill
walking time and the six-minute walking distance (by 17.6 meters),
a clinically meaningful change.
- NR effectively improved walking performance in individuals with
PAD, while resveratrol did not enhance the benefits of NR.
- NR combined with resveratrol did not significantly improve the
six-minute walk distance compared to placebo at the six-month
follow-up.
Relevance
This groundbreaking study is the first to demonstrate NR
supplementation can significantly enhance walking performance in
humans with PAD, and underscores the functional mobility benefits
of NR. By highlighting the therapeutic potential of NR, the
findings open new avenues for improving vascular health and
mobility in PAD patients. Notably, the addition of resveratrol did
not yield further benefits over NR alone, emphasizing NR's unique
role. These promising results underscore the need for further
investigation in larger, randomized clinical trials to fully
explore the benefits of NR in managing PAD and potentially other
age-related conditions.
For additional information on the science supporting Niagen
visit www.chromadex.com.
Forward Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to results from a milestone
phase II clinical study showcasing the promising effects of
nicotinamide riboside (NR) supplementation for people with
peripheral artery disease (PAD). Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. Risks that contribute to the uncertain
nature of these forward-looking statements include the impact of
the COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, comprised of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor,
safety, quality, and transparency, in the dietary supplement space,
ChromaDex is the innovator behind its clinically proven flagship
ingredient, Niagen® (patented nicotinamide riboside, or NR), the
most efficient and superior-quality NAD+ booster available.
Research has shown that reversing NAD+ depletion with Niagen has
positive effects on inflammation and many common age-related health
conditions such as Parkinson’s disease, heart failure, chronic
kidney disease, and autoimmune diseases, among others.
ChromaDex’s robust patent portfolio protects NR and other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com, to
which ChromaDex regularly publishes copies of its press releases,
news, and financial information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240624062781/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director
of Media Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Ben Shamsian Lytham
Partners 646-829-9701 shamsian@lythampartners.com
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 5 2024 まで 6 2024
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 6 2023 まで 6 2024
